Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation

被引：0
作者：
Walid Saliba
机构：
[1] Cleveland Clinic Main Campus,
来源：
American Journal of Cardiovascular Drugs | 2015年 / 15卷
关键词：
Atrial Fibrillation; Warfarin; International Normalize Ratio; Dabigatran; Major Bleeding;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Atrial fibrillation (AF) is a significant problem for the aging population and remains a major factor underlying stroke risk. Warfarin anticoagulation has been proven effective for stroke prevention in AF, but can be difficult to manage and requires frequent monitoring. The non-vitamin K antagonist oral anticoagulants (NOACs) have been shown to be as effective as warfarin for stroke prevention in nonvalvular AF (NVAF) and are associated with a reduced risk of bleeding compared with warfarin. Dabigatran, rivaroxaban, apixaban, and edoxaban have been approved in the USA for reducing the risk of stroke in patients with NVAF. In this article, AF risk assessment is discussed and NOAC phase III clinical trials for the prevention of stroke and systemic embolic events are reviewed. Further, differences in stroke and bleeding outcomes between NOACs are highlighted, the use of NOACs for cardioversion and special patient populations is discussed, and management considerations for patients with AF are reviewed.
引用
收藏
页码：323 / 335
页数：12
相关论文
共 307 条
  • [31] Tsuyuki RT(2013)Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin Br J Clin Pharmacol. 76 455-528
  • [32] Hess PL(2014)Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor Drug Metab Dispos. 42 520-399
  • [33] Mirro MJ(2008)Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects Drug Metab Dispos. 36 386-458
  • [34] Diener HC(2010)Edoxaban transport via P-glycoprotein is a key factor for the drug’s disposition Drug Metab Dispos. 38 448-2255
  • [35] Ruff CT(2012)The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans Drug Metab Dispos. 40 2250-1151
  • [36] Giugliano RP(2009)In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies N Engl J Med. 361 1139-891
  • [37] Braunwald E(2011)Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans N Engl J Med. 365 883-992
  • [38] Camm AJ(2011)Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med. 365 981-2104
  • [39] Hirsh J(2013)Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med. 369 2093-694
  • [40] Fuster V(2011)Apixaban versus warfarin in patients with atrial fibrillation J Clin Pharmacol. 51 687-1414
12345678910